⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for chronic myelogenous leukemia

Every month we try and update this database with for chronic myelogenous leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDSNCT00334074
Acute Myelogeno...
Myelodysplastic...
Chronic Myeloge...
Clofarabine and...
18 Years - 85 YearsBaylor Research Institute
Repeat Dose Safety Study for Compound to Treat Hematologic CancerNCT00881946
Hematologic Mal...
GSK21110183
18 Years - Accenture
Repeat Dose Safety Study for Compound to Treat Hematologic CancerNCT00881946
Hematologic Mal...
GSK21110183
18 Years - Accenture
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerNCT00723099
Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Myeloge...
Chronic Phase C...
Indolent Non-Ho...
Lymphoma
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Plasm...
Recurrent Small...
Recurrent T-Cel...
Refractory Chro...
Refractory Chro...
Refractory Foll...
Refractory Hodg...
Refractory Lymp...
Refractory Mant...
Refractory Smal...
T-Cell Non-Hodg...
Allogeneic Hema...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Total-Body Irra...
Umbilical Cord ...
- 69 YearsFred Hutchinson Cancer Center
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesNCT02639559
Acute Myelogeno...
Acute Lymphobla...
Chronic Myeloge...
Non-Hodgkin's L...
Non-Hodgkin Lym...
Hodgkin Disease
Hodgkins Diseas...
Hodgkin's Disea...
Multiple Myelom...
Myelodysplastic...
Myeloproliferat...
BL-8040
Leukapheresis
Hematopoietic c...
18 Years - 75 YearsWashington University School of Medicine
WT1 for the Detection of Minimal Residual DiseaseNCT00179829
Leukemia
Cancer
WT 1 Testing
- 21 YearsAnn & Robert H Lurie Children's Hospital of Chicago
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic MalignanciesNCT00270881
Acute Myelogeno...
Acute Lymphobla...
Chronic Myeloge...
Myelodysplastic...
Cord blood tran...
TBI
cyclophosphamid...
cytarabine
20 Years - 55 YearsKeio University
Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) InterventionNCT02592447
Chronic Myeloge...
Therapy for Tar...
Wait-List Contr...
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in JapanNCT01464411
Leukemia, Myelo...
Myelogenous Leu...
20 Months - Kanto CML Study Group
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid LeukemiaNCT02709083
Chronic Myeloge...
Chronic Myeloid...
Leukemia
Dasatinib
Imatinib Mesyla...
Nilotinib
17 Years - Emory University
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)NCT00519090
Myelogenous Leu...
Imatinib
Nilotinib (AMN1...
18 Years - Novartis
AHN-12 Biodistribution in Advanced LeukemiaNCT01207076
Acute Myelogeno...
Myelodysplastic...
Acute Lymphobla...
Chronic Myeloge...
90Y-AHN-12
12 Years - Masonic Cancer Center, University of Minnesota
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyNCT00990587
Hematologic Mal...
Acute Lymphocyt...
Chronic Lymphoc...
Myelodysplasia
Acute Myeloid L...
Chronic Myeloge...
Hodgkin's Disea...
Ciclopirox Olam...
18 Years - University Health Network, Toronto
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)NCT00500006
Chronic Myeloge...
Leukemia, Lymph...
MK0457
dasatinib
18 Years - Merck Sharp & Dohme LLC
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesNCT00376519
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
Secondary Myelo...
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
Treg cell infus...
umbilical cord ...
total-body irra...
18 Years - 45 YearsMasonic Cancer Center, University of Minnesota
Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive LeukemiasNCT00811070
Chronic Myeloge...
SKI-606 (Bosuti...
20 Years - 74 YearsPfizer
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsNCT03106779
Chronic Myeloge...
Asciminib
Bosutinib
18 Years - Novartis
Treg Cells for AGVHD in Non-myeloablative UCB TransplantNCT02118311
Hematologic Mal...
T Regulatory ce...
Fludarabine
Cyclophosphamid...
Total Body Irra...
18 Years - 69 YearsMasonic Cancer Center, University of Minnesota
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)NCT00237120
Chronic Myeloge...
Imatinib
15 Years - 74 YearsNovartis
Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesNCT01474681
Acute Myelocyti...
Acute Lymphocyt...
Chronic Myeloge...
Myelodysplastic...
Chronic Lymphoc...
Marginal Zone L...
Follicular Lymp...
Large-cell Lymp...
Lymphoblastic L...
Burkitt's Lymph...
High Grade Lymp...
Mantle-cell Lym...
Lymphoplasmacyt...
HSC835
10 Years - 55 YearsNovartis
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood CancersNCT00089596
Acute Lymphocyt...
Acute Myeloid L...
Myelodysplastic...
Non-Hodgkin Lym...
Chronic Myeloge...
Expansion of um...
12 Years - 60 YearsViaCell
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood CancerNCT00005785
Hematologic Neo...
HIV Infection
GCSF Mobilized ...
- National Institutes of Health Clinical Center (CC)
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell TransplantNCT00571662
Acute Myelogeno...
Acute Lymphocyt...
Chronic Myeloge...
Chronic Lymphoc...
Myelodysplastic...
Multiple Myelom...
Non-Hodgkins Ly...
Hodgkins Diseas...
Peripheral T-ce...
Pentostatin
Total-body irra...
Cyclosporine A ...
Mycophenolate M...
G-CSF
19 Years - 75 YearsUniversity of Nebraska
Specialized Blood Cell Transplants for Cancers of the Blood and Bone MarrowNCT00003838
Myeloproliferat...
Acute Myelogeno...
Chronic Myeloge...
Myelodysplastic...
Acute Lymphobla...
T-cell replete ...
Methotrexate
Cyclosporine
G-CSF
2 Years - 80 YearsNational Institutes of Health Clinical Center (CC)
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) TransplantNCT01244906
Hematologic Neo...
Allogeneic Hema...
18 Years - 75 YearsNorthside Hospital, Inc.
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in JapanNCT00337454
Chronic Myeloge...
Dasatinib
Dasatinib
Dasatinib
Dasatinib
Dasatinib
Dasatinib
20 Years - 75 YearsBristol-Myers Squibb
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML PatientsNCT00499889
Leukemia
Imatinib Mesyla...
Fludarabine (Fl...
Busulfan
Antithymocyte G...
Tacrolimus
Methotrexate
Donor lymphocyt...
Stem Cell Trans...
- 70 YearsM.D. Anderson Cancer Center
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaNCT00171249
Philadelphia Po...
Acute Lymphobla...
Acute Myeloid L...
STI571 400 mg
STI571 600 mg
18 Years - Novartis
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous PlerixaforNCT01696461
Related Donors ...
Acute Myelogeno...
Acute Lymphobla...
Myelodysplastic...
Chronic Myeloge...
Non-Hodgkin's L...
Hodgkin's Disea...
Chronic Lymphoc...
Plerixafor
18 Years - 65 YearsCenter for International Blood and Marrow Transplant Research
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical TrialNCT01004640
Leukemia
DNA analysis
Southern blotti...
cytogenetic ana...
polymerase chai...
- Alliance for Clinical Trials in Oncology
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaNCT00333840
Chronic Myeloge...
imatinib mesila...
interferon-alph...
cytarabine (ARA...
18 Years - 70 YearsNovartis
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNCT03625388
Chronic Myeloge...
Dasatinib
18 Years - Hikma Pharmaceuticals LLC
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic MalignanciesNCT00514722
Acute Myeloid L...
Myelodysplasia
Acute Lymphobla...
Chronic Myeloge...
Multiple Myelom...
Lymphoma, Large...
Lymphoma, Mantl...
Lymphoma, T-Cel...
T-NK Cell Lymph...
Hodgkin Disease
umbilical cord ...
18 Years - 55 YearsUniversity of California, San Francisco
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesNCT02743351
Hematologic Mal...
Acute Myeloid L...
Acute Lymphobla...
Myelodysplastic...
Chronic Myeloge...
Acute Graft-ver...
ProTmune
Control Arm
18 Years - Fate Therapeutics
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisNCT02593123
Hodgkin's Lymph...
Lymphoid Leukem...
Lymphoma
Leukemia
Myeloma
Acute Lymphocyt...
Non Hodgkin Lym...
Chronic Lymphoc...
Multiple Myelom...
Chronic Myeloge...
Myelodysplastic...
Recurrent Acute...
Recurrent Hodgk...
Recurrent Non-H...
Recurrent Plasm...
Recurrent Chron...
Recurrent Chron...
Acute Myelogeno...
mycophenolate m...
Sargramostim
Filgrastim
18 Years - 74 YearsVirginia Commonwealth University
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell TransplantationNCT00038818
Chronic Myeloge...
Multiple Myelom...
Non Hodgkin's L...
Hodgkin's Disea...
Chronic Lymphoc...
CD8 Depleted Do...
- M.D. Anderson Cancer Center
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersNCT03314974
Acute Leukemia
Acute Myeloid L...
Acute Lymphobla...
Lymphoma
Chronic Myeloge...
Plasma Cell Leu...
Myeloproliferat...
Myelofibrosis
Myelodysplasia
Refractory Anem...
High Risk Anemi...
Chronic Lymphoc...
Small Lymphocyt...
Marginal Zone B...
Follicular Lymp...
Lymphoplasmacyt...
Mantle-Cell Lym...
Prolymphocytic ...
Diffuse Large C...
Lymphoblastic L...
Burkitt Lymphom...
High Grade Non-...
Multiple Myelom...
Juvenile Myelom...
Biphenotypic/Un...
MRD Positive Le...
Natural Killer ...
Acquired Bone M...
HSCT with TBI R...
HSCT with Non-T...
- 60 YearsMasonic Cancer Center, University of Minnesota
Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal TumorsNCT00580281
Gastric Cancer
Leukemia
Chronic Myeloge...
blood test, uri...
- Memorial Sloan Kettering Cancer Center
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDSNCT00334074
Acute Myelogeno...
Myelodysplastic...
Chronic Myeloge...
Clofarabine and...
18 Years - 85 YearsBaylor Research Institute
Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In RemissionNCT01901666
Chronic Myeloge...
Short Stature
Growth Hormone
- PIMERIndia
Collect and Assess Tissue Samples From Subjects With Hematologic MalignancyNCT04014764
Acute Myelogeno...
Multiple Myelom...
Myelodysplastic...
Lymphoma
Acute Lymphobla...
Chronic Myeloge...
Myeloproliferat...
This is a non-i...
18 Years - Notable Labs
Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With LeukemiaNCT01204788
Leukemia
Prophylactic Wh...
Therapeutic Whi...
2 Years - M.D. Anderson Cancer Center
Autologous Stem Cell Transplants for Chronic Myelogenous LeukemiaNCT00446173
Leukemia
Busulfan
Cyclophosphamid...
G-CSF
GM-CSF
21 Years - 65 YearsM.D. Anderson Cancer Center
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)NCT00406393
Leukemia, Myelo...
Leukemia, Lymph...
Leukemia, Myelo...
Myelodysplastic...
Tacrolimus
Methotrexate
Sirolimus
2 Years - 60 YearsMedical College of Wisconsin
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaNCT00171249
Philadelphia Po...
Acute Lymphobla...
Acute Myeloid L...
STI571 400 mg
STI571 600 mg
18 Years - Novartis
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) PatientsNCT00493181
Leukemia
Chronic Myeloge...
Chronic Myeloid...
Interleukin-11 ...
- M.D. Anderson Cancer Center
Autologous Transplantation for Chronic Myelogenous LeukemiaNCT01003054
Chronic Myeloge...
Busulfan
Cyclophosphamid...
Imatinib Mesyla...
Autologous Stem...
- 70 YearsM.D. Anderson Cancer Center
Stem Cell Transplantation for Patients With Cancers of the BloodNCT00467961
CML (Chronic My...
CLL (Chronic Ly...
AML (Acute Myel...
Acute Lymphocyt...
MDS (Myelodyspl...
Miltenyi system
18 Years - 75 YearsNational Institutes of Health Clinical Center (CC)
Methods to Enhance the Safety and Effectiveness of Stem Cell TransplantsNCT00378534
Chronic Myeloge...
Acute Myelogeno...
Chronic Lymphoc...
Acute Lymphobla...
Myelodysplastic...
Miltenyi reagen...
Fludarabine
Cyclosporine
Cyclophosphamid...
FILGRASTIM (G-C...
10 Years - 75 YearsNational Institutes of Health Clinical Center (CC)
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesNCT02145039
Acute Leukemias
Burkitt's Lymph...
Chronic Myeloge...
Fludarabine
Cyclophosphamid...
Total Body Irra...
Haploidentical ...
- 74 YearsMasonic Cancer Center, University of Minnesota
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerNCT00602693
Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
umbilical cord ...
Allopurinol
fludarabine pho...
Cyclophosphamid...
Total body irra...
Treg infusion
Sirolimus
18 Years - 75 YearsMasonic Cancer Center, University of Minnesota
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T CellNCT01660607
Myeloid Leukemi...
Acute Myelogeno...
Myelodysplastic...
Lymphoma, Non-H...
Acute Lymphobla...
Myeloproliferat...
Acute Myeloid L...
Acute Leukemia
Chronic Myeloge...
Conventional T ...
13 Years - 60 YearsStanford University
Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or IntolerantNCT00413270
Chronic Myeloge...
nilotinib
18 Years - Novartis
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or IntronNCT00037882
Leukemia, Myelo...
PEG-Intron
- M.D. Anderson Cancer Center
Methods to Enhance the Safety and Effectiveness of Stem Cell TransplantsNCT00378534
Chronic Myeloge...
Acute Myelogeno...
Chronic Lymphoc...
Acute Lymphobla...
Myelodysplastic...
Miltenyi reagen...
Fludarabine
Cyclosporine
Cyclophosphamid...
FILGRASTIM (G-C...
10 Years - 75 YearsNational Institutes of Health Clinical Center (CC)
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)NCT00050531
Leukemia, Myelo...
Gleevec
Peg-alpha inter...
Sargramostim (G...
18 Years - M.D. Anderson Cancer Center
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic MalignanciesNCT00270881
Acute Myelogeno...
Acute Lymphobla...
Chronic Myeloge...
Myelodysplastic...
Cord blood tran...
TBI
cyclophosphamid...
cytarabine
20 Years - 55 YearsKeio University
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesNCT00109707
Chronic Myeloge...
Acute Lymphobla...
Hypereosinophil...
Systemic Mastoc...
Nilotinib
18 Years - Novartis
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme MalignanciesNCT02765997
Acute Myeloid L...
Acute Lymphocyt...
Chronic Myeloge...
Myelodysplasia
Unmanipulated U...
SR-1 UCB
2 Years - 35 YearsMasonic Cancer Center, University of Minnesota
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationNCT01634217
Acute Myelogeno...
Acute Lymphocyt...
Chronic Myeloge...
Non-Hodgkin Lym...
Hodgkin Lymphom...
Chronic Lymphoc...
Multiple Myelom...
Myelodysplastic...
iTreg
18 Years - 75 YearsMasonic Cancer Center, University of Minnesota
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALLNCT00384228
Chronic Myeloge...
Acute Lymphobla...
Nilotinib
20 Years - Novartis
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyNCT00990587
Hematologic Mal...
Acute Lymphocyt...
Chronic Lymphoc...
Myelodysplasia
Acute Myeloid L...
Chronic Myeloge...
Hodgkin's Disea...
Ciclopirox Olam...
18 Years - University Health Network, Toronto
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BPNCT00088231
Acute Myelogeno...
Agnogenic Myelo...
Chronic Myeloge...
Imatinib Mesyla...
PTK 787 (vatala...
15 Years - M.D. Anderson Cancer Center
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid LeukemiaNCT03216070
Chronic Myeloge...
Dasatinib 50 MG
16 Years - Hospital Universitario Dr. Jose E. Gonzalez
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood CancerNCT00975975
Acute Myelogeno...
Acute Lymphocyt...
Chronic Myeloge...
Chronic Lymphoc...
Myelodysplasia
Non-Hodgkin's L...
Hodgkin's Disea...
Multiple Myelom...
Myelofibrosis
Anemia, Aplasti...
Hemoglobinuria,...
Basiliximab
18 Years - Indiana University
Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive LeukemiasNCT00811070
Chronic Myeloge...
SKI-606 (Bosuti...
20 Years - 74 YearsPfizer
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsNCT04795427
Leukemia, Chron...
asciminib
best available ...
18 Years - Novartis
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-CNCT00038649
Myelogenous Leu...
Gleevec
15 Years - M.D. Anderson Cancer Center
Asciminib Roll-over StudyNCT04877522
Chronic Myeloge...
Leukemia, Myelo...
Asciminib singl...
Asciminib
Imatinib
Nilotinib
Bosutinib
Dasatinib
18 Years - Novartis
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic MalignanciesNCT02566395
Acute Lymphobla...
Acute Myelogeno...
Myelodysplastic...
Chronic Myeloge...
Non-Hodgkin Lym...
Hodgkin Lymphom...
Radiation
Cyclophosphamid...
Donor Lymphocyt...
Haploidentical ...
2 Years - 21 YearsNorthwell Health
TALL-104 and Gleevec in Chronic Myelogenous Leukemia PatientsNCT00415909
Chronic Myeloge...
Imatinib Mesyla...
TALL-104 cells
18 Years - M.D. Anderson Cancer Center
A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP PatientsNCT02511340
Chronic Myeloge...
Flumatinib mesy...
18 Years - 75 YearsJiangsu Hansoh Pharmaceutical Co., Ltd.
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated LymphocytesNCT00038870
Acute Myelogeno...
Chronic Myeloge...
Dendritic Cell ...
18 Years - 75 YearsM.D. Anderson Cancer Center
FTS Study in Patients With Advanced Hematologic MalignanciesNCT00867230
Myelodysplastic...
Leukemia
FTS
18 Years - M.D. Anderson Cancer Center
Safety And Efficacy Of BosutinibNCT02501330
Chronic Myeloge...
Bosutinib
0 Years - Pfizer
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersNCT03314974
Acute Leukemia
Acute Myeloid L...
Acute Lymphobla...
Lymphoma
Chronic Myeloge...
Plasma Cell Leu...
Myeloproliferat...
Myelofibrosis
Myelodysplasia
Refractory Anem...
High Risk Anemi...
Chronic Lymphoc...
Small Lymphocyt...
Marginal Zone B...
Follicular Lymp...
Lymphoplasmacyt...
Mantle-Cell Lym...
Prolymphocytic ...
Diffuse Large C...
Lymphoblastic L...
Burkitt Lymphom...
High Grade Non-...
Multiple Myelom...
Juvenile Myelom...
Biphenotypic/Un...
MRD Positive Le...
Natural Killer ...
Acquired Bone M...
HSCT with TBI R...
HSCT with Non-T...
- 60 YearsMasonic Cancer Center, University of Minnesota
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TARNCT01611298
Acute Lymphobla...
Acute Myelogeno...
Chronic Myeloge...
Myelodysplastic...
Hodgkin Lymphom...
Non-Hodgkin Lym...
Tetanus
3 Years - 70 YearsBaylor College of Medicine
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)NCT00760877
CHRONIC MYELOGE...
Nilotinib
Imatinib
18 Years - Novartis
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)NCT03578367
CML
Chronic Myeloge...
Leukemia, Myelo...
Hematologic Dis...
Asciminib add-o...
Imatinib
Nilotinib
Asciminib singl...
18 Years - Novartis
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in IsraelNCT00159003
Acute Myeloid L...
Chronic Lymphoc...
Chronic Myeloge...
18 Years - Hadassah Medical Organization
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: